134 related articles for article (PubMed ID: 8751580)
1. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.
Clary BM; Coveney EC; Blazer DG; Philip R; Lyerly HK
Surgery; 1996 Aug; 120(2):174-81. PubMed ID: 8751580
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
3. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
4. Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system.
Clary BM; Coveney EC; Blazer DG; Philip R; Philip M; Morse M; Gilboa E; Lyerly HK
J Immunother; 1997 Jan; 20(1):26-37. PubMed ID: 9101411
[TBL] [Abstract][Full Text] [Related]
5. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.
Connor J; Bannerji R; Saito S; Heston W; Fair W; Gilboa E
J Exp Med; 1993 Apr; 177(4):1127-34. PubMed ID: 8459207
[TBL] [Abstract][Full Text] [Related]
6. Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo.
Glick RP; Lichtor T; Kim TS; Ilangovan S; Cohen EP
Neurosurgery; 1995 Mar; 36(3):548-55. PubMed ID: 7753355
[TBL] [Abstract][Full Text] [Related]
7. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
8. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
Kircheis R; Küpcü Z; Wallner G; Wagner E
Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
[TBL] [Abstract][Full Text] [Related]
10. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals.
Coveney E; Clary B; Iacobucci M; Philip R; Lyerly K
Surgery; 1996 Aug; 120(2):265-72; discussion 272-3. PubMed ID: 8751592
[TBL] [Abstract][Full Text] [Related]
11. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
12. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
13. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
14. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells.
Gansbacher B; Zier K; Cronin K; Hantzopoulos PA; Bouchard B; Houghton A; Gilboa E; Golde D
Blood; 1992 Dec; 80(11):2817-25. PubMed ID: 1450408
[TBL] [Abstract][Full Text] [Related]
15. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
Karp SE; Farber A; Salo JC; Hwu P; Jaffe G; Asher AL; Shiloni E; Restifo NP; Mulé JJ; Rosenberg SA
J Immunol; 1993 Feb; 150(3):896-908. PubMed ID: 8423345
[TBL] [Abstract][Full Text] [Related]
16. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
17. Sarcoma cells engineered to secrete IFN-gamma or IL-2 acquire sensitization to immune cell killing via different mechanisms.
Flemming CL; Patel PM; Box G; Eccles SA; Collins MK
Cytokine; 1997 May; 9(5):328-32. PubMed ID: 9195131
[TBL] [Abstract][Full Text] [Related]
18. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model.
Matsumoto G; Sunamura M; Shimamura H; Kodama T; Hashimoto W; Kobari M; Kato K; Takeda K; Yagita H; Okumura K; Hamada H; Matsuno S
Surgery; 1999 Mar; 125(3):257-64. PubMed ID: 10076609
[TBL] [Abstract][Full Text] [Related]
20. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]